drugset / Trial / NCT01783951
Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer
Phase 1/2
Completed
63 enrolled
Capital Medical University
Duke University · collabGeneplus-Beijing Co. Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1 based chemotherapy for advanced gastric cancer.
Timeline
- Start
- 2013-02-01
- Primary completion
- 2018-02
- Completion
- 2018-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-CIK | Cell therapy | — | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | S-1 | Small molecule | 40 mg | — |
| Background | S-1 | Small molecule | 50 mg | — |
| Background | S-1 | Small molecule | 60 mg | — |